Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Jia Wei, Doctor
CONTACT
Lead
Tongji Hospital
This open-label, single-arm study is designed to evaluate the efficacy and safety of in vivo CAR-T cell therapy in patients with relapsed/refractory B-cell lymphoma/leukaemia. This study incorporates two pretreatment regimens: lymphodepletion and non-lymphodepletion. In the lymphodepletion regimen: Upon enrolment, leukapheresis will be performed. Subjects will then undergo 3-5 days of lymphodepleting therapy with fludarabine and cyclophosphamide, followed by concomitant intravenous infusion of the JY231 preparation and autologous peripheral blood mononuclear cell(PBMC) via a double-lumen catheter. In the non-lymphodepletion regimen: Patients will receive direct intravenous injection of the JY231 preparation. Following infusion, subjects will undergo safety and efficacy assessments for up to 3 months. For those achieving sustained remission at 3 months post-infusion, follow-up will be conducted for at least 24 months to evaluate disease control status.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
